Results 11 to 20 of about 1,697,934 (260)
Invasive candidiasis (IC) is a term that refers to a group of infectious syndromes caused by a variety of Candida species, 6 of which cause the vast majority of cases globally.
J. A. Schroeder +2 more
semanticscholar +10 more sources
Invasive candidiasis is the most common fungal disease among hospitalized patients in the developed world. Invasive candidiasis comprises both candidemia and deep-seated tissue candidiasis.
B. Kullberg, M. Arendrup
semanticscholar +10 more sources
Invasive candidiasis in children
The prevalence of invasive candidiasis (IC) in pediatric hospitals is from 4,3 to 15,2 per 10,000 hospitalized, in ICU – from 3,5 to 7 cases per 1,000, with HSCT – 2,9%. The average length of stay of a patient in the hospital before the development of IC
N. N. Klimko, O. P. Kozlova
doaj +3 more sources
Invasive candidiasis is an important health-care-associated fungal infection that can be caused by several Candida spp.; the most common species is Candida albicans, but the prevalence of these organisms varies considerably depending on geographical location.
P. Pappas +4 more
semanticscholar +7 more sources
INVASIVE CANDIDIASIS IN NON-HEMATOLOGICAL PATIENTS.
Candida is one of the most frequent pathogens isolated in bloodstream infections, and is associated with significant morbidity and mortality. In addition to haematological patients, there are several other populations with a substantial risk of ...
Malgorzata Mikulska +3 more
doaj +4 more sources
Diagnosing Invasive Candidiasis [PDF]
ABSTRACT Cultures are negative in ∼50% of invasive candidiasis. Data are emerging for the performance of nonculture tests such as mannan/antimannan, Candida albicans germ tube antibody, 1,3-β- d -glucan, PCR, and the T2Candida panel in diagnosing both candidemia and deep-seated ...
C. Clancy, M. Nguyen
semanticscholar +3 more sources
BACKGROUND Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials.
George R Thompson +16 more
semanticscholar +1 more source
BACKGROUND Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after ...
G. Thompson +136 more
semanticscholar +1 more source
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-hospital morbidity and mortality. The limited number of antifungal drug classes and the emergence of multi-resistant Candida species, such as Candida auris and ...
F. Lamoth
semanticscholar +1 more source
Invasive candidiasis encompassing Candida bloodstream infections and deep-seated candidiasis can become a persistent health problem. These infections are caused by Candida species and have high morbidity and mortality rates.
F. Riera +6 more
semanticscholar +1 more source

